Aradigm Corporation Awarded National Institutes of Health (NIH) Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections With Pulmaquin and Lipoquin
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
HAYWARD, Calif.--(BUSINESS WIRE)--The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products Pulmaquin® and Lipoquin®. The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Dr. Luiz Bermudez at the Oregon State University, Corvallis, will lead the laboratory research as a part of the consortium funded by this grant of approximately $278,000.
Help employers find you! Check out all the jobs and post your resume.
HAYWARD, Calif.--(BUSINESS WIRE)--The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products Pulmaquin® and Lipoquin®. The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Dr. Luiz Bermudez at the Oregon State University, Corvallis, will lead the laboratory research as a part of the consortium funded by this grant of approximately $278,000.
Help employers find you! Check out all the jobs and post your resume.